Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Preventive Cardiology
•
Primary Care
How do you decide between obtaining routine, outpatient ETT versus stress TTE when screening for CAD, especially given insurance company preference on ETTs?
Related Questions
Would it be reasonable to consider switching from a high intensity statin therapy to PCSK9 inhibitor vs. adding adjunct lipid lowering medications for a patient with known coronary artery calcifications, LDL in the mid-100 range pre-statin with worsening A1C levels?
For women with known autoimmune diseases, how do you approach ASCVD risk stratification when deciding to start a statin or aspirin for primary prevention?
What is your approach to a newly diagnosed LBBB in individuals >70 years old who are free of any signs or symptoms of heart disease and without other significant ASCVD risk factors besides age?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
For isolated and very high lipoprotein (a) levels (LDL of > 140, has an Lp(a) > 100) in a patient with no cardiac symptoms or risk factors, would you start lipid lowering treatment, such as with a PCSK9i if they develop statin intolerance?
What is your approach to statin and/or PCSK9i initiation and counseling in a patient who has an HDL above 100, LDL within normal range, but markedly elevated calcium score exceeding 1000?
Would you consider adding niacin to the lipid lowering regimen in statin-intolerant patients who cannot afford PCSK9i or bempedoic acid?
What are your thoughts on the use of icosapent ethyl in clinical practice for patients with hypertriglyceridemia, and its safety profile such as increased risk of atrial fibrillation?
When would you consider ordering additional testing such as hs-CRP, lipoprotein A levels, or CAC scoring to further risk stratify otherwise healthy pre-menopausal women with a prior history of pregnancy-related hypertension, diabetes, or premature births?
How does the TACTiC trial's success with a web app for statin self-management influence your stance on nonprescription statins for primary prevention amidst statin underuse?
